Is KPTI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KPTI. It does not provide personalized investment advice.

KPTI (Karyopharm Therapeutics Inc.) Stock Analysis - Financials

Karyopharm Therapeutics Inc. (KPTI) is a publicly traded Healthcare sector company. As of November 2, 2026, KPTI trades at $0.11 with a market cap of $15.02M and a P/E ratio of -0.04. KPTI moved -85.17% today. Year to date, KPTI is -90.79%; over the trailing twelve months it is -88.89%. Its 52-week range spans $0.31 to $10.99. Analyst consensus is buy with an average price target of $5.84. Rallies surfaces KPTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are KPTI's key financials?

KPTI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KPTI recently traded at $0.11. Market cap is $15.02M. P/E ratio is -0.04. Revenue is $146.62M.

KPTI Key Metrics

Key financial metrics for KPTI
Metric	Value
Price	$0.11
Market Cap	$15.02M
P/E Ratio	-0.04
EPS	$-14.16
Dividend Yield	0.00%
52-Week High	$10.99
52-Week Low	$0.31
Volume	19.59M
Avg Volume	0
Revenue (TTM)	$146.62M
Net Income	$-224.74M
Gross Margin	0.00%

KPTI Analyst Consensus

2 analysts cover KPTI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.84.

Common questions about KPTI

What are KPTI's key financials?: KPTI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KPTI recently traded at $0.11. Market cap is $15.02M. P/E ratio is -0.04. Revenue is $146.62M.
Is KPTI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KPTI. It does not provide personalized investment advice.